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ABSTRACT
Background: Limited evidence supports the common public health
guideline that children >2 y of age should consume dairy with
reduced fat content.
Objectives: We aimed to investigate the effects of whole-fat
compared with reduced-fat dairy intake on measures of adiposity
and biomarkers of cardiometabolic risk in healthy 4- to 6-y-old
children.
Methods: The Milky Way Study enrolled 49 children (mean ± SD
age: 5.2 ± 0.9 y; 47% girls) who were habitual consumers of whole-
fat dairy, then randomly assigned them in a double-blind fashion
to remain on whole-fat dairy or switch their dairy consumption to
reduced-fat products for 3 mo. Primary endpoints included measures
of adiposity, body composition, blood pressure, fasting serum lipids,
blood glucose, glycated hemoglobin (HbA1c), and C-reactive protein
(CRP) and were assessed at baseline and study end. Pre- and
postintervention results were compared using linear mixed models,
adjusted for growth, age, and sex.
Results: Dairy fat intake was reduced by an adjusted (mean ± SEM)
12.9 ± 4.1 g/d in the reduced-fat compared with the whole-
fat dairy group (95% CI: –21.2, –4.6 g/d; P = 0.003), whereas
dietary energy intakes remained similar (P = 0.936). We found no
significant differential changes between dairy groups in any measure
of adiposity, body composition, blood pressure, or fasting serum
lipids, glucose, HbA1c, and CRP.
Conclusions: Our results suggest that although changing from
whole-fat to reduced-fat dairy products does reduce dairy fat intake, it
does not result in changes to markers of adiposity or cardiometabolic
disease risk in healthy children. This trial was registered at
www.anzctr.org.au as ACTRN12616001642471. Am J Clin Nutr
2021;00:1–18.
Keywords: Milky Way Study, dairy fat, dietary fat, pediatric, ran-
domized controlled trial, cardiometabolic disease, air displacement
plethysmography, BodPod, cholesterol, child-centered care
Introduction
Systematic reviews and meta-analyses of prospective adult
cohorts have shown that core dairy whole foods—milk, cheese,
and yogurt—are associated with lower risks of cardiometabolic
dysfunction (1), including obesity (2); cardiovascular disease
(CVD) (3–6); coronary heart disease (3–8); heart failure (7);
hypertension (5, 9); stroke (5–8, 10); metabolic syndrome (MetS)
(5, 11, 12) and its components (12); and all-cause mortality (3).
In children, increased total dairy consumption is associated with
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lower adiposity (13). Associations between dairy intake and type
2 diabetes risk are more nuanced (14), with mostly beneficial
associations (8, 15–20).
Although dairy forms part of a healthy diet in many countries
(21–23), whole-fat dairy is thought to increase cardiometabolic
risk (24–27). In Australia, whole milk is considered essential
for infant growth, but everyone >2 y old is advised to consume
mostly reduced-fat dairy (22). Traditionally, 2 main reasons are
given: the “adiposity hypothesis” suggests that higher energy
density in whole-fat dairy may increase ad libitum energy intake
and body weight. The “saturated fat hypothesis” considers that
the 60%–70% saturated fat fraction in dairy fat raises serum LDL
cholesterol, considered a major risk factor for CVD (27–30).
However, cardiometabolic risk projection is generally based on
single-nutrient research or component outcomes in adults (31–
33), and it is increasingly evident that matrix effects in complex
whole foods modify the health impacts of individual nutrients
(34). Hence, consuming dairy fat in cheese lowers serum LDL
cholesterol compared with similar amounts of dairy fat in butter
(35, 36).
Observational studies of adults show that dairy fat is not
commonly associated with weight gain or cardiometabolic
dysfunction when consumed as part of typical dietary patterns
(28, 31, 32, 37, 38). The National Heart Foundation of Australia
recently changed position, from recommending reduced-fat dairy
choices for all adults toward considering whole-fat milk, yogurt,
and cheese to be acceptable for healthy adults (27, 39). This
represents a substantial shift toward accepting whole-food dairy
as part of a healthy dietary pattern (40). In children, the largely
observational evidence shows consistently that public health
policy encouraging reduced-fat dairy after 2 y of age is unlikely to
prevent or reduce childhood obesity or excess adiposity (41–43).
Observational studies may suffer from reverse causality or
confounding (44, 45), and good-quality evidence in the form
of clinical trials is needed to inform pediatric dairy guidelines.
To date, as far as we know there have been no double-blind
randomized controlled trials (RCTs) directly comparing the
effects of whole-fat and reduced-fat dairy diets on comprehensive
measures of child body composition (outside of BMI and waist
circumference) or cardiometabolic risk factors. We aimed to
investigate the effects of 12 wk of whole-fat compared with
reduced-fat dairy intake on cardiometabolic risk factors in healthy
4- to 6-y-old children in an RCT. We hypothesized there would
be no significant between-group differences in adiposity or in
cardiometabolic risk factors.
Methods
Study design and trial registration
The Milky Way Study is a double-blinded comprehensive
pilot RCT investigating the effects of dairy fat on health-related
outcomes in young Western Australian children. The study in-
volved assessments and sample collection at study clinics before
and after a 3-mo dairy intervention. The Milky Way Study was
registered prospectively with the Australian New Zealand Clini-
cal Trials Registry as ACTRN12616001642471 (https://www.an
zctr.org.au/Trial/Registration/TrialReview.aspx?id=371803) and
approved by the Edith Cowan University (ECU) Human Research
Ethics Committee (Project no. 14990).
Participants were recruited and completed the dairy interven-
tion and relevant assessments for this study between January and
December 2017, with all clinical assessments carried out at the
ECU Joondalup campus in Perth. Primary study outcomes were
1) changes in a variety of common adiposity measures including
anthropometrics (body weight, height, waist circumference, and
neck circumference, and derived indexes such as BMI) and
body composition (body fat mass and body fat percentage
measured using a COSMED BodPod with pediatric option), and
2) changes in cardiometabolic risk factors {serum lipids (fasting
total cholesterol, fasting HDL cholesterol, fasting triglycerides,
and derived fasting LDL cholesterol); serum glycemic mea-
sures [fasting blood glucose and fasting glycated hemoglobin
(HbA1c)]; the serum inflammatory biomarker fasting C-reactive
protein (CRP); and systolic and diastolic blood pressure, assessed
using a Dinamap recorder with pediatric cuff}. Secondary
outcome measures included intakes of different food groups to
provide data on dairy intake and overall diet composition, and
erythrocyte fatty acid composition to verify compliance with the
intervention.
Development of the study protocol
The Milky Way study protocol (Supplemental Study Pro-
tocol) details prestudy preparation, such as a blind taste-test
by children (n = 8) to check the acceptability of the proposed
study dairy products. We have previously published details of
our pretrial community consultation (46) and child-centered
research model: procedures developed to optimize parental study
involvement and child compliance with clinical assessments
have been detailed in our feasibility study (47). Study details
conducted as per the supplied protocol have been shortened here
in favor of clinically relevant detail.
Study participants
We recruited participants from the coordinating university,
community childcare centers, and parent social communities and
organizations, and via social media snowball recruitment, articles
in local newspapers, and a current affairs segment on television.
Although Australian guidelines to change to reduced-fat milk
apply to children from the age of 2 y (22), we chose slightly
older children owing to the nature of the assessments to be used
and feedback from our community consultation. Healthy children
aged 4–6 y were eligible for inclusion in the study if they were
daily consumers of ≥1 serving of whole-fat dairy, with >70% of
their dairy consumed or prepared at home; lived within 20 km
of the study university campus; and were able to complete the
study protocol. Key exclusion criteria included diagnosis of or
medications for cardiometabolic or gastrointestinal dysfunction;
dairy allergy; antibiotic use over the past 3 mo; or having a body
weight < 9.5 kg, because guidelines for the total blood volume
that can safely be taken from children stipulate age-related body
weights (48). This low body weight was chosen to exclude
extreme outliers in advance, as detailed in the study protocol,
ensuring safe blood draws of ≤7 mL from all participants.
Parents were recruited by telephone and sent parent and child
information leaflets by email. At the start of the first clinic visit,
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informed consent. After their first baseline clinic visit, each child
was block randomly assigned, stratified by age and sex, into
the whole-fat or the reduced-fat dairy group by an independent
researcher picking an opaque sealed envelope for each participant
from the appropriate one of 6 buckets (6 strata, comprising 2
sexes and 3 ages for each: 4, 5, or 6 y). The envelopes provided
equal proportions of each dairy group; 6 envelopes/bucket were
replenished when empty.
Dairy intervention
In this double-blind RCT, 4- to 6-y-old children who were
habitual consumers of whole-fat dairy were randomly assigned
to either continue consuming whole-fat dairy foods, or to switch
to reduced-fat versions of these dairy foods. The 3-mo dairy
intervention began when the first dairy products were provided
to take home, immediately after completion of all baseline
assessments. The goal of a real-world study changed our original
intention to recommend daily dairy intake according to dietary
guidelines (22); instead, we requested ongoing intake of ≥1
serving of dairy per day, with no order limits. Children continued
their habitual diet but replaced all dairy with the study dairy
products, provided at no cost.
Dairy product selection, blinding, and delivery.
Study dairy products were all purchased at local supermarkets,
relabeled by independent researchers, packaged for optimum
cold storage, and, after the first on-site collection, delivered
regularly to most families at home. Apart from fat content, each
product pair was closely matched for brand and nutrient content
to minimize product variations, including differences in bovine
diet (37, 49) and sugar content. Fat content for whole-fat products
was ∼3.5 g/100 mL for milk, ∼35 g/100 g for cheese, ∼9 g/100 g
for yogurt, and ∼3.5 g/100 g for dairy dessert and custard; we
note the greater accuracy in reporting 3.5% dairy fat (50) than
the 4% estimates in the prospective study documentation. For
reduced-fat dairy, we aimed for 2 g/100 mL for milk, 15 g/100 g
for cheese, 2 g/100 g for yogurt, and 2 g/100 g for dairy dessert
and custard, based on product availability, suitability, likely child
acceptability, and compliance with Food Standards Australia
New Zealand criteria for reduced-fat foods (51). All cream and
butter items provided were whole fat, or 50% fat-reduced, to help
boost group dairy fat intake differences in an ad libitum diet.
We offered a wide range of dairy foods to help maintain child
interest and intake. This was balanced against possible variability
in outcomes, given that different dairy products have potentially
different effects on health (34–36, 40).
Final decisions on products were informed by child prestudy
blind taste assessments, supply availability, and the ability to
blind product pairs to prevent identification of the dairy group
from a product’s unique shape, color, or markings. A dietitian
recorded each participant’s habitual diet at their first clinic visit,
using a “typical day” dietary recall (referencing the past 7 d,
weekdays compared with weekends compared with holidays)
combined with a study-specific dairy FFQ, with prompting
around situational dairy intake contexts. Given the paucity of
validated dairy FFQs for this age group (52), we designed these
tools to enable provision of appropriate dairy products and to
provide support for the detailed food record data collected at
baseline and end of intervention.
Dairy products offered to replace habitual intake included
the core dairy products, milk, cheese, and yogurt, along with
custard and chocolate dairy desserts, (sour) cream, and butter.
Further choice requests were accommodated if a suitable product
pair could be sourced. Yogurt was supplied in individual tubs
(all ≤200 g) and options available included vanilla (French-
style, unstrained pot-set compared with conventional, sweeter
versions) and strawberry or berry (real fruit pieces); plain yogurt
was supplied if specifically requested. Cheese choices comprised
mild hard cheese (supplied as a whole food block or sliced;
we did not offer highly processed cheese slices) and cream
cheese (supplied as foil-wrapped wedges). Cream was provided
as fresh pouring/whipping cream or sour cream. Dairy desserts
comprised individual chocolate desserts (all ≤175 g) and plain
custard (∼150 g/serving, in 500-g containers). We did not supply
ice cream, owing to food safety concerns around maintaining
temperatures during deliveries.
To ensure compliance with the study dairy protocol, we
included advice to create a dedicated fridge space for each
child at a suitable height, and relabeled all participant dairy
with each child’s name prominent for their own “dairy section”;
recommended that parents regularly involve children in their food
preparation, and that children remind parents to use their study
dairy; noted the suitability of individual items like cheese slices,
cream cheese, and yogurts specifically for school lunchboxes, and
of individual dairy desserts for temporary carers, to ensure study
dairy consumption out of home; suggested making and freezing
typical family communal dishes, such as lasagna, specifically
for the child; recommended preparing and storing the child’s
own grated cheese, sour cream toppings, ice cream, etc., and
adding these to child portions served first from communal family
dishes prepared without these ingredients; and asked families to
share successful recipes (e.g., ice cream) that used our study
dairy. Family instructions were particularly detailed around
separation and use of dairy when siblings were participating
simultaneously.
Participant data relating to dairy requests, supply, and
consumption (weight of dairy product supplied less weight
returned) were stored in an electronic database (Microsoft Access
2016 database management system), coded to maintain clinical
researcher blinding. All weekly or fortnightly home deliveries
were in accordance with the study protocol, and ensured we
maintained the dairy temperature at ≤2◦C throughout; parents
who worked nearby could choose to collect the dairy at
prearranged times.
Assessment of dairy intervention compliance and adverse
event reporting.
Eligibility and ongoing compliance criteria included partici-
pants consuming ≥1 serving of dairy (preferably milk) per day,
where a serving comprised a 250-mL glass of milk, 40 g cheese,
or a 200-g tub of yogurt (22). Fortnightly compliance checks,
initially by telephone and later by email, enabled assessment of
each child’s mean daily intake of the supplied dairy products;
potential compliance issues and solutions detailed in the study
protocol proved relevant. Parental feedback requested included
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medical occurrence affecting their child and not necessarily due
to the dairy intervention.
Child clinic assessments
Anthropometric and body composition assessments, blood
pressure measurement, and blood draws were generally split over
2 preintervention baseline clinics, and repeated at a single final
clinic visit in the last week of the dairy intervention. We have
noted here where equipment varies from the study protocol: such
changes were dictated by manufacturer upgrades or by practical
experience gained in prestudy practice clinics with 4- to 6-y-old
children, and all changes provided equal or improved accuracy
of results. Parents completed a sociodemographic questionnaire
at baseline. Children were excluded from further participation
if they dissented to both body fat percentage and blood tests
at baseline. Although we have previously defined assessment
“success” (a result was obtained) as distinct from “compliance”
(the child was prepared to have a go on the day) for our study
child-centered research (47), “compliance” as used here has
the more traditional meanings: that a procedure was followed
satisfactorily and/or a quantifiable result was obtained.
Anthropometrics and body composition.
A trained researcher measured child waist and neck circumfer-
ence in the standing position using a Lufkin Executive Thinline
2-m clinical steel tape measure (W606PM), according to standard
protocols (53, 54), and used a SECA 763 digital stadiometer
(SECA Ltd.) to determine height. Each measurement included
≥3 readings taken to the nearest 0.1 cm; ≥2 that agreed to
within 0.1 cm were averaged. Body composition was measured
in the BodPod (COSMED) chamber using radiation-free air
displacement plethysmography and a 2-compartment model (55)
to determine fat mass and lean (fat-free) mass to within 0.001 kg
and 0.01%. Body weight was reported to within 0.001 kg (1 g),
using the integral calibrated electronic scale supplied with the
BodPod.
The BodPod was fitted with a pediatric option (BodPod
Pediatric OptionTM GS model, COSMED USA Inc.), validated
for use in children aged 2–6 y (55). Participants refrained from
food, drink, and physical activity for 1.5 h before clinics, removed
jewelry, and dressed in close-fitting bathing suits or active wear
with bathing caps. All related parental communication included
warnings to ensure that children had no recent ear problems, in
anticipation of slight pressure changes in the BodPod chamber.
Anthropometric indexes calculated included BMI {weight
(kg)/[height (m)]2}; waist-to-height ratio [waist (cm)/height
(cm)]; neck-to-waist [neck (cm)/waist (cm)], neck-to-height
[neck (cm)/height (cm)], and neck-to-waist-to-height ratios [neck
(cm)/waist (cm)/height (m)]; fat mass index {FMI; body fat
mass (kg)/[height (m)]2}; and lean (fat-free) mass index {LMI;
lean mass (kg)/[height (m)]2} (56). US CDC child growth
charts were used to determine BMI-for-age percentiles (57). The
commonly used BMI is regarded as a limited surrogate measure
of obesity, including in children, because it does not account
for the distribution of body lean and fat mass (56, 58). Given
that no 1 measure has been clearly identified as superior to
others in children, we therefore aimed to measure “adiposity”
in a variety of different ways. Waist-to height ratio includes a
measure of abdominal obesity, and may prove a better predictor
of CVD risk than BMI (58), whereas according to the equation
BMI = FMI + LMI, relative health risk could be assumed to
increase with fat mass but to decrease with lean mass (56) [in
the 2-compartment model used, body fat (or %) + lean mass (or
%) = body mass (or 100%)].
Blood pressure.
Blood pressure measurements were taken seated at rest,
using a calibrated Dinamap ProCare 300 Monitor (GE Medical
Systems) with the appropriate pediatric cuff determined by arm
circumference. A minimum of 2 measurements was averaged for
statistical analysis (59).
Blood tests.
All blood test clinics followed overnight fasting. A 23 G BD
Vacutainer blood collection set (Becton Dickinson and Company)
was used to collect ≤4 vials (6.0 mL total) of blood according to
pediatric research guidelines (48, 57, 60). The lithium heparin
collection tube was centrifuged for 10 min at 4◦C and 2500 × g;
together with an unprocessed K2EDTA tube, it was transported to
a local pathology laboratory for analysis within 2 h of the blood
draw. A second K2EDTA tube was centrifuged as before; plasma
was removed, and erythrocytes were saline washed (0.1% NaCl)
and centrifuged again, as previously. All plasma (500 μL) and




Blood samples were analyzed by PathWest, a National
Association of Testing Authorities–accredited laboratory. Unless
specified otherwise, all analyses were performed on an Abbott
Architect c16000 (Abbott Laboratories) clinical chemistry an-
alyzer, using the centrifuged samples from the lithium heparin
tubes. Lipid profiling was performed using standard enzymatic
assay techniques. LDL cholesterol was calculated using the
Friedewald equation (61) and we calculated a total-to-HDL
cholesterol ratio (total cholesterol/HDL cholesterol) and non-
HDL cholesterol (total cholesterol minus HDL cholesterol). Im-
munoassay was used to determine fasting serum plasma glucose
and ferritin. We included testing for the inflammatory marker
CRP, using latex immunoassay; however, CRP values >5.0 mg/L
were deleted from analyses based on suspected acute illness or
injury. HbA1c was determined on a Cobas c501 system (Roche
Holding AG), using the unprocessed K2EDTA tube samples.
Erythrocyte fatty acids.
Erythrocyte samples stored and transported at −80◦C were
analyzed at the University of Western Australia Medical Research
Foundation for red cell membrane fatty acids by GLC (Agilent
Technologies Model 7980A Gas Chromatograph), using an
SPTH 2560 column (100 m × 0.25 mm, 0.2-μm film thickness;
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at 4◦C/min, and hydrogen as carrier gas (1 mL/min) at a split
ratio of 30:1. Individual fatty acids were calculated as a relative
percentage of the peak total area, with the total set at 100%.
Dietary assessment
We chose weighed 3-d food records for Milky Way Study
dietary assessment as a reasonable burden to ask of parents. At the
first baseline clinic parents were asked to record everything their
child consumed over 3 consecutive days. We provided electronic
scales (Propert 5 kg Slimline stainless-steel digital scales), and
a dietitian demonstrated accurate measurement techniques using
food models. Parents were asked to note daily whether the record
accurately represented their child’s usual eating habits, and if
not to describe why. Parents returned completed records at the
final baseline clinic. These 3-d food records were repeated over
the final weekend of the intervention. A dietitian reviewed each
record on receipt at clinic visits and sought parental clarifi-
cation for any potentially ambiguous or implausible items or
quantities.
Each food record, together with supplied recipe and food
packaging nutrient information, was entered into FoodWorks
10 Professional software for dietary energy, nutrient, and dairy
product analysis (Xyris Software; updated after our study
protocol, this version includes major food composition tables:
AusFoods 2019, AusBrands 2019, Australian Food Composition
Database) and independently verified.
Assessment of dietary compliance and validity of food record
reporting.
Individual food records were adjusted to exclude single days
where a child’s diet was deemed unusual; the remaining days
were then averaged. Unusual daily intake was determined by a
dietitian after parental clarification (e.g., due to reported illness).
We allowed for natural large daily variations in children’s intake,
given innate adjustment for energy needs (62); in addition, we
compared daily energy intake (kJ) against national standardized
estimated energy requirements (EERs) for children (63). Each
participant’s final mean energy intake was then assessed against
upper and lower cutoffs, calculated as 3 SDs from the mean
population daily energy intake at that time point, to eliminate
participants with prolonged extreme intakes.
Measuring dairy fat intake can be difficult within studies
because dairy fat is included in many foods and fat content can
vary across similar foods (64, 65). Erythrocyte odd-numbered
SFAs, pentadecanoic acid (15:0) and heptadecanoic acid (17:0),
as well as trans-palmitoleic acid (t16:1n–7), were investigated
as dairy-specific biomarkers based on previous research studies
(66–71) to provide objective verification of food record reporting.
Statistical analyses
Power calculation.
For the primary outcomes, the pilot study was estimated
to have the following power to detect realistic between-group
changes in 40 healthy children over a 12-wk dairy intervention:
1) body fat percentage: 80% power to detect ≥3.3%, or 50%
power to detect ≥2%, based on reported child study mean ± SD
of 19.2% ± 7.8% (determined in 3- to 8-y-olds, using DXA)
(72) and 25.6% ± 4.1% (in 2- to 6-y-olds, using a BodPod) (55);
2) LDL cholesterol: 80% power to detect ≥0.73 mmol/L, or
50% power to detect ≥0.51 mmol/L; and 3) HDL cholesterol:
80% power to detect ≥0.27 mmol/L, or 50% power to detect
≥0.19 mmol/L (73, 74). We therefore aimed to recruit ≤55
children, to allow for sample loss.
Data analysis.
Clinic data were entered into spreadsheets via independent
double-entry, and exported to IBM SPSS Statistics version 26.0
for Windows (2019) for all data analysis. Sociodemographic,
body composition, blood test, dairy, and dietary variables
were compared for between-group differences at baseline,
using chi-square tests for categorical variables (reported as
counts/frequencies and percentages) and independent-sample
t tests for continuous variables (reported as mean ± SD or
mean ± SEM). Where data were below the threshold of detection,
a median midpoint value was used. Changes () in dependent
variables (cardiometabolic endpoints, nutrients, and erythrocyte
fatty acids) over the intervention were compared using paired-
sample t tests and reported as mean ± SEM, as per the equation:
3−mo (time) change = Combined group (final − baseline) (1)
Nonparametric Mann–Whitney U tests and Wilcoxon signed
rank tests replaced independent-sample and paired-sample t tests,
respectively, where variable distribution was not normal.
Relevant postintervention correlations are reported between
promising erythrocyte fatty acid dairy biomarkers and dairy fat
intakes (in grams per day and adjusted for dietary energy), for
comparison with reported correlations in both intervention (75,
76) and observational dairy fat studies (70, 77, 64). Where
variables were not normally distributed, Kendall’s tau-beta (τ )
was used instead of Pearson’s correlation coefficient (r) for all
bivariate correlations. In variation from the original protocol to
use a repeated-measures ANOVA we used linear mixed models
instead, because these are more effective in handling missing
data. Analysis undertaken using repeated-measures ANOVA
yielded substantively similar results. Linear mixed models in
SPSS compared intervention changes () from baseline in
cardiometabolic, nutrient, and erythrocyte fatty acid variables,
producing parameter estimates (contrast hypotheses) as per the
programmed equation:
3−mo (dairy group × time) change
= Reduced−fat group (final − baseline)
−Whole−fat group (final − baseline) (2)
The 3-mo change, or dairy group × time interaction, reported
for mixed models represents the net difference for the combined
group, with each dairy group adjusted for baseline. Where group
means moved in opposite directions during the intervention, such
as an increase in one group and a decrease in the other, a larger net
difference was produced. The final mean “direction” of change of
all participants from baseline is recorded as positive or negative
as per equation 2.
SPSS paired-sample analyses included only those who
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definition, but linear mixed models have the potential to allow
for individual participant variables missing at 1 time point.
Linear mixed models can adjust for covariates at each time
point, not just at baseline, hence providing an allowance for
growth effects. In addition to traditional growth variables of
weight and height, we also adjusted for growth via changes in
neck and waist circumference. This provided additional data on
growth and on weight distribution. Where body composition–
dependent variables or indexes included ≥1 growth variable
(e.g., BMI includes height and weight), these were not used in
growth adjustment. Because there is a possibility that type of
dairy consumption may have influenced both growth rate and
health markers, as a sensitivity analysis we repeated the models
adjusting only for changes in height and weight. Refitting without
adjustment for growth in neck or waist circumference did not
affect the significance of any of the reported findings, and hence
has not been reported here.
No sociodemographic variables improved the fit or signifi-
cance of these models and none was included in the final models.
We modeled an additional random effect to account for sibling
pairs in the study; given that this did not substantively affect the
parameter estimates, and the variance component associated with
sibling pairs was small and nonsignificant for all key analyses, our
results presented in the article do not include clustering for sibling
pairs. We used a random intercept and first-order autoregressive
variance structure to account for repeated measures and adjusted
for fixed effects—the covariates age, sex, and the 4 growth
variables—as appropriate. Values are reported as means ± SEMs,
and 95% CIs from adjusted mixed-model analyses have been
included to indicate effect size for changes in primary and
secondary outcomes.
The main purpose of this study was to determine if dietary
guidelines should continue to recommend mainly reduced-fat
dairy for children, via a real-world intervention—such as a
healthy population maintaining their habitual diet. Although our
investigation was an RCT, this primary purpose took precedence
over determining if providing children and families with blinded
dairy products would achieve certain outcomes, such as reducing
children’s body fat. Unforeseen considerations, such as extensive
sample losses for some endpoints, in addition factored into
our decision not to pursue intention-to-treat considerations,
as originally intended, but to conduct a per-protocol analysis
only. Although we appreciate that not all families base their
dietary choices on dietary guidelines, and revisions to guidelines
will not necessarily change dietary habits for all families, the
study aims to contribute useful information to help inform
decisions about what should be included in dietary guidelines.
All tests were 2-tailed and applied a significance threshold of
0.05.
Results
We assessed 176 applications for children to participate in
the Milky Way Study, of which 119 were excluded and 8 chil-
dren were withdrawn after enrolment. Randomization followed
completion of the first baseline clinic. In total, 25 children were
allocated to the whole-fat dairy (control) group, of which 23
completed baseline testing and 22 completed the intervention,
and 24 were allocated to the reduced-fat (intervention) group,
with no losses. For the Consolidated Standards of Reporting
Trials (CONSORT) flow diagram showing the Milky Way
Study participant numbers for the 3-mo dairy fat intervention,
see Figure 1.
Participant characteristics
The Milky Way Study included 49 children (47% girls)
with a mean age of 5.2 ± 0.9 y at the first baseline clinic.
The mean intervention duration was 12.3 ± 0.9 wk. Three
children (2 girls) withdrew during the study (dropout rate of
6%), owing to assessment refusal (n = 1) and parent burden
with sample collection (n = 1) at baseline, and refusal of
further study participation (n = 1) during the intervention.
Baseline sociodemographic, clinical, and lifestyle characteristics,
including key endpoint variables, are compared between dairy
groups in Table 1.
Including nonidentical twins and 2 siblings who participated
at separate times owing to age constraints, 6 eligible sibling pairs
participated in the study. Each child was individually randomly
assigned, producing 3 pairs of siblings split between the dairy
groups, as well as 2 pairs in the whole-fat dairy group and 1 pair
in the reduced-fat group. Fitting models to account for any effects
of first-degree relatives showed a negligible impact of variance
and covariance parameters on key analysis results at the sibling
pair level. In addition, close comparison of siblings’ food records
showed reasonable parental compliance with instructions around
separate provision and recording of foods, portion sizes, and dairy
foods.
Participant compliance with the study protocol
We have previously published detailed participant compliance
rates for body composition, blood pressure, and phlebotomy
(47). We recruited an additional 9 children, 22.5% above the
40 required for the pilot study, to achieve adequate statistical
power for our primary study outcomes. This was achieved for
body fat percentage changes over the intervention (n = 40).
Despite anticipating some sample losses due to child dissent, an
integral part of our child-centered approach, participant sickness
and/or refusal were the major factors affecting the final outcome
numbers at each time point; BodPod malfunction at the study
midpoint affected mainly final assessments (n = 5). Analysis
for each endpoint variable was conducted using the full data
available for that variable; however, participant numbers for
intervention-related changes were particularly affected where
statistical analysis excluded missing items pairwise.
All participants maintained their dairy intakes at or above
the minimum requirement of 1 serving/d, based on mean dairy
calcium intake of 250–300 mg/d, calculated from total dairy
product supply and consumption over 3 mo (dairy nutrient
data are provided in Table 2; additional data on dairy product
consumption are included in Supplemental Table 1). No adverse
effects from the supplied dairy were reported. Childhood illnesses
affected intake results variably at both time points, particularly
over winter assessments. One participant was excluded from
the final food record dietary analysis when illness restricted
her mean energy intake over each of the 3 d to below one-
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Randomly assigned (n = 49)
FIGURE 1 Milky Way Study Consolidated Standards of Reporting Trials (CONSORT) flow diagram detailing study participant recruitment, random
assignment, and retention pre- and postintervention. 1Unanticipated family and/or child health-related issues (n = 6); prescribed antibiotics after enrolment
(n = 2). 2Parent time burden (n = 1); child declined both primary outcome assessments (blood test and body composition analysis) (n = 1).
for extreme intakes (population mean ± 3 SD). Water intake
proved difficult to track and had to be estimated; however, milk
and other drink items appeared to be appropriately reported. No
participants appeared to over- or underreport intake to a degree
that would have led us to exclude their reported intakes from
analyses.
Intervention cardiometabolic changes
Anthropometrics and body composition.
There were no significant between-group changes in body
composition over the intervention after adjustment for growth,
sex, age, and group baseline differences in linear mixed models
(Table 3), as per Equation 2, provided above. Individual
children’s height increased by ≤3.5 cm over the 3 mo, with
weight changes of ≤1.7 kg. We observed a trend toward a
differential change in the BMI percentile, with a borderline
significant reduction in the whole-fat compared with the reduced-
fat group [P (dairy group × time) = 0.054].
There were no meaningful differences in changes in neck
or waist circumference between the intervention and control
groups in the study. Child postintervention neck circumference
results correlated strongly with their BMI (Pearson’s r = 0.70;
P < 0.001), weight (r = 0.86; P < 0.001), waist circumference
(r = 0.75; P < 0.001), and age (Kendall’s tau-beta, τ = 0.27;
P = 0.008). There was a consistent ratio of ∼1:2:4 for participant
neck:waist:height measurements (cm) across clinic visits.
Blood pressure.
There was no significant effect of the dairy intervention on
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TABLE 1 Comparison of Milky Way Study baseline sociodemographic, clinical, dietary, and lifestyle characteristics for children randomly assigned to the
WF (control) or to the RF (intervention) dairy group1
WF dairy2 RF dairy2
Characteristics2 n
Percentage/





Participant 25 51 24 49
Female 13 57 10 43
Male 12 46 14 54
Age, y 25 5.2 ± 0.9 24 5.2 ± 0.9 0.555
Female 13 5.2 ± 0.8 10 5.1 ± 0.7
Male 12 5.3 ± 1.0 14 5.3 ± 1.0
Mother4 23 23
BMI at baseline, kg/m2 21 24.8 ± 4.5 22 25.1 ± 5.0 0.821
Education 23 23 0.681
Year 12 or less 3 13.0 4 17.4
Tertiary 20 87.0 19 82.0
Marital status 23 23 0.406
Living with partner 1 4.3 4 17.4
Divorced/separated 2 8.7 2 8.7
Married 19 82.6 17 73.9
Single 1 4.3 0 0
Father 23 24
BMI at baseline, kg/m2 19 26.2 ± 3.0 22 27.0 ± 3.2 0.446
Education 23 23 0.501
Year 12 or less 5 21.7 6 26.1
Trade 1 4.3 3 13.0
Tertiary 17 73.9 14 60.9
Household income, AUD 21 24
<$100,000 5 23.8 7 29.2 0.935
$100,000–$150,000 7 33.3 8 33.3
>$150,000 5 23.8 4 16.7
Rather not say 4 19.0 5 20.8
Child clinical and lifestyle
Child weight, kg 25 18.3 ± 0.6 24 19.1 ± 0.5 0.331
BMI, kg/m2 25 15.1 ± 0.2 24 15.1 ± 0.2 0.972
Body fat, % 23 20.1 ± 1.3 24 20.4 ± 1.4 0.876
Systolic BP, mm Hg 19 94 ± 3 20 100 ± 2 0.048
Diastolic BP, mm Hg 19 56 ± 1 20 58 ± 1 0.076
Total cholesterol, mmol/L 15 4.3 ± 0.1 21 4.1 ± 0.1 0.193
LDL cholesterol, mmol/L 15 2.6 ± 0.1 21 2.3 ± 0.1 0.113
HDL cholesterol, mmol/L 15 1.4 ± 0.1 21 1.5 ± 0.1 0.340
Triglycerides, mmol/L 15 0.60 [0.40, 0.70] 21 0.50 [0.40, 0.75] 0.391
Non-HDL cholesterol, mmol/L 15 2.9 ± 0.1 21 2.5 ± 0.1 0.104
Total/HDL cholesterol 15 3.1 ± 0.2 21 2.7 ± 0.1 0.078
Dietary energy, kJ/d 23 5767 ± 179 24 5628 ± 209 0.619
Dietary total fat, kJ%/d 23 32.2 ± 1.4 24 34.1 ± 0.9 0.257
Dairy fat, g/d 23 15.0 [11.8, 21.3] 24 15.5 [11.1, 23.5] 0.915
Dairy fat, kJ%/d 23 10.7 [8.6, 14.2] 24 10.3 [7.5, 16.4] 0.831
Outdoor activity, h/d 23 3.0 ± 1.2 24 2.6 ± 1.9 0.167
Indoor physical activity, h/d 21 2.9 ± 1.6 24 2.6 ± 1.4 0.574
1Family sociodemographic characteristics from Milky Way Study Family Questionnaires [total returned n = 47 (94%); 2 surveys not returned owing to
child withdrawals]; some individual data items were not completed, e.g., child indoor activity was not reported for 2 children in these returned surveys. BP,
blood pressure; kJ%/d, percentage of total dietary kilojoules per day, or adjusted for energy intake; RF, reduced-fat; WF, whole-fat.
2Values for sociodemographic and child activity variables are percentages of the total number/counts for categorical variables, or means ± SDs for
continuous variables (all included here are normally distributed). Values for child clinical and dietary variables are means ± SEMs (or medians [IQRs] where
data proved not normally distributed).
3Dairy group comparisons used chi-square tests for categorical variables and independent-samples testing for continuous variables: t tests where data
showed a normal distribution and Mann–Whitney U tests where data proved not normally distributed.
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TABLE 2 Comparison of Milky Way Study mean daily intervention dairy product nutrient consumption (products supplied less weighed returns) by the WF
(control) and the RF (intervention) dairy groups over 3 mo1
WF group RF group Group comparison2
Dairy (per day)3 Mean ± SEM Mean ± SEM Difference ± SEM P
Total intake, g 432 ± 34 471 ± 46 − 39 ± 58 0.613
Energy, kJ 2441 ± 197 1578 ± 131 864 ± 233 0.001
Energy, % diet kJ 41.6 ± 2.9 25.7 ± 2.1 15.8 ± 3.6 <0.001
Total fat, g 41.8 ± 3.7 16.6 ± 1.5 25.3 ± 4.0 <0.001
Total fat, % dairy kJ 62.5 ± 1.4 38.9 ± 1.4 23.6 ± 2.0 <0.001
Total fat, % diet kJ 26.1 ± 2.0 10.1 ± 0.9 16.0 ± 2.2 <0.001
Saturated fat, g 26.9 ± 2.3 10.2 ± 0.9 16.7 ± 2.5 <0.001
Saturated fat, % dairy kJ 40.3 ± 0.7 23.9 ± 0.9 16.4 ± 1.1 <0.001
Saturated fat, % diet kJ 16.8 ± 1.2 6.2 ± 0.6 10.6 ± 1.4 <0.001
Protein, g 19.2 ± 1.5 21.5 ± 1.8 − 2.3 ± 2.4 0.429
Protein, % dairy kJ 13.7 ± 0.5 23.3 ± 0.6 − 9.6 ± 0.8 <0.001
Protein, % diet kJ 5.7 ± 0.4 5.9 ± 0.5 − 0.3 ± 0.7 0.696
Carbohydrate, g 29.8 ± 2.6 32.4 ± 2.9 − 2.6 ± 3.9 0.629
Carbohydrate, % dairy kJ 20.0 ± 1.0 32.7 ± 1.2 − 12.7 ± 1.5 <0.001
Carbohydrate, % diet kJ 8.2 ± 0.7 8.4 ± 0.7 − 0.2 ± 1.0 0.848
Sugar, g 27.1 ± 2.5 29.4 ± 2.7 − 2.3 ± 3.6 0.582
Sugar, % dairy kJ 18.2 ± 0.9 29.6 ± 1.1 − 11.4 ± 1.4 <0.001
Sugar, % diet kJ 7.5 ± 0.6 7.6 ± 0.7 − 0.2 ± 0.9 0.865
Calcium, mg 636 ± 49 746 ± 66 − 110 ± 84 0.613
Calcium, mg/1000 kJ dairy 268 ± 10 472 ± 11 − 205 ± 15 <0.001
Calcium, mg/1000 kJ diet 110 ± 8 120 ± 10 − 10 ± 13 0.443
Sodium, mg 402 ± 30 388 ± 31 14.4 ± 43.3 0.253
Sodium, mg/1000 kJ dairy 268 ± 10 472 ± 11 − 205 ± 15 <0.001
Sodium, mg/1000 kJ diet 69.2 ± 5.0 65.1 ± 5.6 4.1 ± 7.5 0.591
1A total of 46 participants (94%) on WF (n = 22) or RF (n = 24) dairy completed the 3-mo intervention. mg/1000 kJ dairy, milligrams per 1000 kJ of
daily dairy intake; mg/1000 kJ diet, milligrams per 1000 kJ of daily dietary energy intake; RF, reduced-fat; WF, whole-fat; % dairy kJ, percentage of total
dairy kilojoules per day (adjusted for dairy energy intake); % dietary kJ, percentage of total dietary kilojoules per day (adjusted for dietary energy intake).
2Intervention dairy product nutrient intakes over 3 mo were compared using independent-sample t tests; values are means ± SEMs. Mann–Whitney U
tests were used where products were not normally distributed. Results are all considered significant where P (2-tailed) < 0.05.
3Dairy products were supplied to match usual intake, with orders adjusted fortnightly to maintain interest. Product pairs were closely matched for brand
and nutrient content: fat content for WF dairy products was ∼3.5 g/100 mL for milk, ∼35 g/100 g for cheese, ∼9 g/100 g for yogurt, and ∼3.5 g/100 g for
dairy dessert and custard; for RF dairy, we aimed for 2 g/100 mL for milk, 15 g/100 g for cheese, 2 g/100 g for yogurt, and 2 g/100 g for dairy dessert and
custard; all creams and butters were whole fat, or 50% fat-reduced. Adjustment for dietary energy intake was derived from final 3-d food records: n = 21 for
the RF group (n = 24 completed the intervention: 2 participants did not return food records and 1 participant was excluded when sickness over the 3 d
reduced energy intake to <25% of estimated energy requirements and outside the population cutoff of mean ± 3SD); n = 22 for the WF group.
Lipid profile, glycemic, and inflammatory markers.
There were no significant between-group differences in
lipid concentrations in adjusted models over the intervention
(Table 5). Both dairy groups showed a similar small, nonsignif-
icant increase in LDL-cholesterol (+0.1 mmol/L) and decline
in HDL-cholesterol concentration (−0.1 mmol/L). Seventy-six
percent of children (75% at baseline; 77% postintervention)
had normal-sensitivity CRP values <1 mg/L, preventing trend
analysis within the healthy range (<5 mg/L). Supplemental
Table 2 provides a fuller range of cardiometabolic endpoint
variables.
Intervention dietary and dairy nutrient changes
A subset of relevant nutrient intervention-related changes from
weighed 3-d food records is shown in Table 6, with a fuller range
of nutrients, including those contributed by dairy intake, provided
in Supplemental Table 3. Headings and footnotes account for
final participant numbers and missing data in each dairy group.
We found a lower mean daily energy intake (15.7% at baseline;
13.5% at end of intervention) than predicted by child standardized
EERs. Erythrocyte fatty acid dairy biomarkers used to assess
intervention compliance have been reported below; however,
analysis of individual dietary fatty acids and fat-soluble vitamins
has not been included here.
Dairy fat intake was reduced by an adjusted 12.9 ± 4.1 g/d
(95% CI: −21.2, −4.6 g/d; P = 0.003) in the reduced-fat
compared with the whole-fat dairy group, although participant
dietary energy intakes remained similar (P = 0.936). After ad-
justment for dietary energy, this differential reduction amounted
to 7.7 ± 2.2 kJ%/d (95% CI: −12.2, −3.2 kJ%/d; P = 0.001).
The dairy saturated fat fraction showed similar results (adjusted
3-mo net reduction = 8.8 ± 2.5 g/d; 95% CI: −14.0, −3.7 g/d;
P = 0.001, or 5.1 ± 1.4 kJ%/d; 95% CI: −7.9, −2.3 kJ%/d;
P = 0.001).
As a biomarker of dairy fat, erythrocyte pentadecanoic acid
was positively associated with dairy fat intake changes over
the intervention, both in grams per day (Kendall’s τ = 0.47;
P < 0.01) and adjusted for dietary energy (Pearson’s r = 0.53;
P < 0.01). This significant response to the dairy fat intervention
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(dairy group × time)
Variable3 WF RF Mean ± SEM P Mean ± SEM 95% CI P
Systolic BP, mm Hg 17 18
Baseline 93 ± 3 100 ± 2
3-mo change 3 ± 2 − 1 ± 2 1 ± 1 0.677 − 3 ± 2 −8, 2 0.239
Diastolic BP, mm Hg 17 18
Baseline 55 ± 1 58 ± 1
3-mo change 2 ± 1 − 1 ± 1 0 ± 1 0.646 − 2 ± 2 −6, 2 0.251
1BP, blood pressure; RF, reduced-fat; WF, whole-fat.
2Sample losses: of 49 children that attended the baseline clinic visit and 46 that attended the final clinic (94%; 3 dropped out before the final clinic),
n = 43 children (88% of the total) provided ≥2 BP readings; 8 of these (4 each at baseline and postintervention) provided ≥2 readings at only a single time
point, reducing the number of paired samples to 35 (71% of the total); child dissent was responsible for all sample losses.
3Unadjusted paired differences: paired-samples t tests were used to compare dairy group intervention changes where the data set was normally
distributed. Differences are considered significant where P < 0.05.
4Adjusted model differences: linear mixed models were used to adjust for fixed confounders in dairy group comparisons (no random factors achieved
significance or improved the fit of any of the models), using contrast hypotheses (parameter estimates) to estimate group variable changes over the
intervention. Each variable was adjusted for sex, age changes (incorporating individual length of intervention, between 11.5 and 15 wk), and child growth
over the intervention. Child growth variables that achieved significance in models included changes in height, weight, neck circumference, and waist
circumference: the latter 2 were considered to better allow for adipose tissue deposition (or loss) during growth spurts. Covariates in the model: mean age
over the intervention = 5.4 y; mean weight over the intervention = 19.0 kg; mean height over the intervention = 111.9 cm; mean waist circumference over
the intervention = 52.0 cm; and mean neck circumference over the intervention = 25.3 cm. Linear mixed models do not necessarily remove participants
missing either initial or final test results. Significant differences are indicated where P (dairy group × time) < 0.05.
reduction in reduced-fat group = −0.036% ± 0.008%; 95%
CI: −0.053%, −0.018%; P < 0.001). A smaller, nonsignificant
association of heptadecanoic acid with dairy fat intake (r = 0.18)
achieved borderline significance for the adjusted intervention
dairy group × time interaction (3-mo net comparative reduction
in reduced-fat group = −0.024% ± 0.012%; 95% CI: −0.049%,
0.001%; P = 0.055). We were unable to distinguish trans-
palmitoleic acid from the cis-isoform. (Data for these dairy
biomarkers are not included in either the article or the supple-
mental tables.)
The reduced-fat dairy group increased their intake of dietary
sodium over the dairy intervention by 301 ± 109 mg/d. After
adjustment for dietary energy (mg Na/1000 kJ), this amounted
to a substantial increase in sodium intake compared with the
whole-fat dairy group (for dairy group × time, adjusted 3-mo
net difference = 54 ± 19 mg/1000 kJ; P = 0.008). When
adjusted further for intake changes in dairy sodium, the reduced-
fat dairy group effectively increased their dietary sodium by
241 mg/d (15.2%) from baseline, amounting to an additional
44 mg/1000 kJ (15.6%) consumed per day compared with the
whole-fat group (baseline mean sodium intake: 1583 ± 53 mg/d
or 282 ± 9 mg/1000 kJ; n = 47; these baseline population mean
values are not included in either the article or the supplemental
tables).
Discussion
Our RCT provided no evidence for differential effects of
whole-fat compared with reduced-fat dairy on measures of
adiposity or cardiometabolic risk factors in healthy 4- to 6-y-old
children over 3 mo, despite substantially increased intake of core
dairy products. For adiposity measures, 2 previous interventions
to reduce dairy fat in habitual diet in schoolchildren similarly
found no significant differences between intervention and control
groups for body weight, BMI, or waist circumference in 145
Australian 4- to 13-y-olds (65), or in indigenous Mexican 6- to
16-y-old school boarders drinking reduced-fat (n = 180) or skim
milk (n = 148), compared with whole-milk controls (n = 134)
(78). Our RCT shows in addition no significant differences in
body fat percentage or FMI, all in direct opposition to the so-
called “adiposity hypothesis.” Our data are further supported
by the observational evidence. A systematic review and meta-
analysis of observational studies reported lower odds of child
overweight or obesity (OR: 0.61; 95% CI: 0.52, 0.72; P < 0.0001)
with regular intake of whole-fat milk (41); a systematic review
of observational and intervention studies found no associations
between whole-fat dairy products and increased child body
weight or adiposity (42), while a comprehensive analysis of the
evidence-base in children found little evidence for the influence
of dairy fat content on body fatness (43).
Furthermore, cross-sectional (79, 80) and prospective cohort
(81) studies have shown that 2- to 6-y-old children with (severe)
obesity were less likely to consume whole milk than those in
the healthy weight range (adjusted OR: 0.77; 95% CI: 0.60,
0.98; P = 0.031) (81); this effect was repeated in cohort
studies of overweight or obese participants aged 2–20 y (81–
83). Researchers have questioned whether this relation could be
bidirectional, causal, or due to public health recommendations
affecting parental choices around supply (81). Our RCT recruited
healthy young children consuming mostly whole-fat dairy.
However, we noted a trend toward a lower BMI percentile in the
whole-fat relative to the reduced-fat group (P = 0.054), which
matches emerging observational evidence (41, 81) questioning
the recommendation to provide reduced-fat dairy to healthy
children. In adults, whole-fat compared with reduced-fat dairy
has been associated with neutral or beneficial effects on body
composition in intervention studies (84–86), and in a systematic
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although some interventions have found adverse effects on body
weight where energy intake is ad libitum (87, 88).
We found no significant effect of the dairy intervention on
blood pressure. Our mean results were similar to the relevant
50th percentile ranges established for nonoverweight children
(n = 13,547; age 2–9 y) participating in the European multicenter
IDEFICS (Identification and prevention of Dietary- and lifestyle-
induced health EFfects In Children and infantS) study (59).
In male adolescents, diastolic blood pressure was inversely
associated with both types of dairy (89). In adult observational
and intervention studies, neither systolic nor diastolic blood
pressure has been associated with increased intake of dairy
products (5, 12, 90) or dairy fat (84, 86, 91).
Fasting serum glucose and lipids in both Milky Way Study
groups were not differentially affected by the dairy intervention:
not even a trend was apparent. Likewise, in an Australian child
cluster education intervention (65), reducing dairy fat did not
significantly affect adjusted serum lipids after 12 wk, while in
Mexican boarding schools (78), changing to reduced-fat or skim
milk for 4 mo did not significantly affect serum triglycerides
or total:HDL cholesterol ratios, because both total- and HDL-
cholesterol concentrations reduced (42). In contrast, a significant
relative change in LDL (−0.28 mmol/L) in the skim milk group
(78) may have been influenced by intervention-related dietary
changes, as explored below. The observational evidence-base
(92) also largely shows that saturated fat, dairy fat, or high-fat
core dairy foods are not detrimentally associated with CVD risk,
risk indexes, or proxy markers (particularly LDL) in adults (37,
90, 93), in adolescents (89), and in children (1–16 y old) (94).
Our study demonstrated significant changes in dairy fat
consumption over 3 mo, supported by significant correlations of
erythrocyte pentadecanoic acid with dairy fat intake. Despite this,
daily energy intakes remained similar. This finding matches that
from the child cluster intervention to reduce dairy fat or screen
time (65). However, adults with MetS (n = 72) supplied with
3.3 servings of whole- or reduced-fat dairy per day increased
their dietary energy compared with limited dairy consumption
(P < 0.001), suggesting relative failure to balance ad libitum
energy intake (87). Whereas young children generally do eat
according to their energy needs, environmental and social factors
can affect intake in older children (95). In the home food choices
are limited to what parents provide, and depend largely on cost,
convenience, and perceived health benefits (96). Changing 1
aspect of a diet can have ramifications for overall diet quality (97):
for example, in Mexican boarding schools children randomly
assigned to reduced-fat milk increased intake of daily tortillas by
26%, while those on skim milk ate 57% more tortillas than the
control group (78). Although evaluation of food group changes
was not an aim of our study, the reduced-fat group increased their
dietary sodium intake by 241 mg/d, or an additional 44 mg Na for
each 1000 kJ consumed, after adjustment for small changes in the
whole-fat dairy group and in total dairy intake. This amounted to
a substantial comparative increase in this group of 15.2% from
the mean population baseline, or 15.6% higher when adjusted for
dietary energy intake.
As a double-blind RCT, our comprehensive pilot study
has many notable strengths. Our provision of blinded dairy
products at no cost to participants removed cost obstacles toward
compliance, and the design of the study helped limit researcher
and family bias. Another important strength of our study was the
use of repeated 3-d weighed food records, with verification by
a dietitian, as well as erythrocyte fatty acid analysis to validate
group differences in dairy fat intake. We recruited healthy, routine
consumers of whole-fat dairy to extend the transferability of
our research to the larger population of healthy children. To
allow for rapid and individual child growth spurts, we adjusted
statistical models for changes in waist and neck circumference, as
well as height and weight, as significant indicators of childhood
growth and distribution of body weight between adipose and lean
tissue. Sensitivity analysis to refit the models without adjustment
for growth in neck or waist circumference did not affect the
significance of our reported findings.
We note some important limitations. Three months was
potentially inadequate to detect all effects of differential dairy
fat intake. The pilot study was not powered to detect small
changes in main outcomes. Although we took care to follow
a child-centered approach (47), blood draws were potentially
distressing for children. We respected children’s decisions to
dissent to assessments. This contributed to a lack of complete
data, particularly for serum-based risk biomarkers. Hence, our
null results may have been partly due to a lack of power. Lack
of an intent-to-treat analysis in our RCT may be considered a
limitation. However, given our primary goal was to inform dietary
guidelines, our focus was on the biological effects of actual
consumption of reduced- compared with whole-fat dairy foods
on healthy children. Loss of sample size for serum biomarker
results added extra information to inform our decision to conduct
statistical analyses on a per-protocol basis only, because we were
unable to analyze the full randomized groups for some endpoints.
However, because we could not find even the slightest trend for
a differential change for serum lipids and glucose, it is unlikely
that a lack of power or of intent-to-treat analyses caused us to
miss major diet effects on these endpoints.
Future research following a larger number of children over a
longer time would further strengthen our findings; in addition,
this could investigate whether different dairy products have
different effects on study endpoints. Given cost considerations,
however, a community-based setting where advice is given on
the types of dairy to consume (similar to the dietary guidelines),
rather than providing dairy, might prove more feasible, less
prohibitively expensive, and better reflect the real-world setting.
We recommend future research continue to use child-friendly
principles to provide a positive participant experience, and make
appropriate allowances for equipment malfunction.
In conclusion, our results suggest that healthy children can
safely consume whole-fat dairy products without increased
adiposity or adverse cardiometabolic effects. With consideration
of our results and previous research, future revisions of dietary
guidelines should consider recommending that children can
consume either whole-fat or reduced-fat dairy: this would help
simplify parental dairy choices and child health concerns. To
our knowledge, our study is the first such dairy intervention in
preadolescent children, and our findings support the accumulated
evidence that public health policy encouraging reduced-fat dairy
after 2 y of age is unlikely to prevent or reduce childhood obesity
or excess adiposity, or improve biomarkers of cardiometabolic
disease risk.
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